FDG-PET/CT useful in evaluating response to melanoma drugs

01/11/2012 | AuntMinnie.com (free registration)

Patients with melanoma who had partial metabolic response to bevacizumab plus ipilimumab, determined through FDG-PET/CT scans, had longer disease-free survival compared with patients who had stable or progressive metabolic disease, according to Dana-Farber Cancer Institute researchers. "While the results are preliminary and further studies are needed, these results suggest both contrast-enhanced CT and FDG-PET may be important imaging biomarkers of efficacy for these therapeutic targets in this clinical setting," said researcher Dr. Pamela DiPiro.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health